Stockreport

AIM ImmunoTech Announces Final Approval of Novel Cancer Therapy Patent in Japan Combining Ampligen with Checkpoint Inhibitors [Yahoo! Finance]

AIM ImmunoTech Inc.  (AIM) 
PDF AIM ImmunoTech Inc. AIM also intends to pursue Japanese Orphan Drug Designation for Ampligen in treatment of pancreatic cancer OCALA, Fla., March 18, 2026 (GLOBE NE [Read more]